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Edited by Beat ImhofAbstract Melanoma cell adhesion molecule (MCAM), an
adhesion molecule belonging to the Ig superfamily, is an endothe-
lial marker and is expressed in diﬀerent epithelia. MCAM is ex-
pressed as two isoforms diﬀering by their cytoplasmic domain:
MCAM-l and MCAM-s (long and short). In order to identify
the respective role of each MCAM isoform, we analyzed
MCAM isoform targeting in polarized epithelial Madin–Darby
canine kidney (MDCK) cells using MCAM-GFP chimeras. Con-
focal microscopy revealed that MCAM-s and MCAM-l were ad-
dressed to the apical and basolateral membranes, respectively.
Transfection of MCAM-l mutants established that a single dileu-
cine motif (41-42) of the cytoplasmic domain was required for
MCAM-l basolateral targeting in MDCK cells. Although double
labelling experiments showed that MCAM-l is not a component
of adherens junctions and focal adhesions, its expression on baso-
lateral membranes suggests that MCAM-l is involved in epithe-
lium insuring.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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MCAM1. Introduction
Melanoma cell adhesion molecule (MCAM)/CD146 is a
113 kDa cell adhesion glycoprotein belonging to the Ig super-
family [1–3]. Its extracellular domain consists in 5 Ig domains
(V–V–C2–C2–C2), a transmembrane domain and a cytoplas-
mic region [1]. MCAM presents homophilic interactions but
also interacts with heterophilic ligands [4–8].
Human MCAM/CD146 was ﬁrst identiﬁed as a melanoma
progression antigen [9,10]. MCAM is also a diﬀerentiation
marker of intermediary placental trophoblast, and is expressed
in mammary lobular and ductal epithelium [11–14]. Endothelia
and smooth muscle cells of blood vessels express also strongly
MCAM [3,6,15]. CD146, detected in endothelial progenitors
such as angioblasts or mesenchymal stem cells, is used as aAbbreviations: MCAM, melanoma cell adhesion molecule; C2, C2C12
mouse myogenic cell line; MDCK, Madin–Darby canine kidney cell
line
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ogenesis and vascular development [3,17,18]. MCAM pre-
sented a complex expression pattern in endothelial cells being
located at cell–cell junction but also on apical membranes [15].
However these studies did not take into account that
MCAM is expressed as two isoforms diﬀering by the cytoplas-
mic region generated by alternative splicing of exon 15 [2,6,19].
These isoforms are named MCAM-l and MCAM-s for long
and short cytoplasmic tail which are 21 and 43 aminoacid long,
respectively. They share 16 aminoacids including a putative
PKC phosphorylation site. Due to a splice-induced frameshift,
MCAM-s exhibits a speciﬁc C-terminus that might interact
with a PDZ domain. MCAM-l speciﬁc cytoplasmic domain
contains an additional PKC site, a dileucine motif, and a
YXXL motif which are conserved in vertebrates [2]. Most
MCAM positive cells express both isoforms and generally
MCAM-l is more prominent than the MCAM-s isoform
[2,6], (Guezguez et al., submitted for publication). In this re-
port, we show that in polarized epithelial Madin–Darby canine
kidney (MDCK) cells, the MCAM-s and MCAM-l isoforms
are addressed to apical and basolateral membranes, respec-
tively. MCAM-l basolateral targeting requires a cytoplas-
mic dileucine motif and double labelling experiments showed
that MCAM-l is not located in adherens junctions and focal
adhesions.2. Materials and methods
2.1. cDNA and plasmid constructs
To obtain the MCAM-GFP construct, the chicken MCAM-l (long
isoform) and MCAM-s (short isoform) were ampliﬁed by polymerase
chain reaction (PCR) using speciﬁc primers as described previously [6].
Then, the cDNAs were inserted in a pcDNA3-GFP vector (Clontech,
Palo Alto, CA), placing the MCAM sequence in frame with sequence
encoding GFP at the C-terminus.
Recombinant sequences encoding mutated cytoplasmic and extracel-
lular domain of MCAM-l were obtained by PCR using speciﬁc primers
(see Table 1). The PCR products were subcloned in the pCRII-Topo
(Invitrogen Inc.,UK).Recombinant sequences ofMCAM-lmutated for
extracellular regions were inserted in the pCRII-Topo placing the
mutated MCAM sequence in frame with peptide signal sequence.
Then, the cDNAs were digested with HindIII/BamHI and inserted in a
pcDNA3-GFP vector as described above.
The MCAM-l mutant in which the two Leucine (residues 603 and
604) were substituted by arginine and methionine residues-hereafter
termed MCAM (LL/RM), was constructed by in vitro mutagenesis
using Quick-change XL site directed mutagenesis kit according to
supplier’s instructions (Stratagene, La Jolla, CA, USA). Brieﬂy, com-
plementary primers (22 nM) and 50 ng of MCAM-l-GFP cDNAblished by Elsevier B.V. All rights reserved.
Table 1
Primers used for mutagenesis and RT-PCR experiments
cDNA Expt Amplicon size (bp) Primer sequences
MCAM-long PCR 1878 (F) 5 0-CCCAAGCTTGGCAGCGAGCATGGCTGG-30
(R) 50-CGGGATCCCGGTTTCTCAGATCGATGTATTTC-30
MCAM-short PCR 1752 (F) 5 0-CCCAAGCTTGGCAGCGAGCATGGCTGG-30
(R) 50-CGGGATCCCGGATCGATGTATTTCTCGCTATG-30
MCAM-lD59 PCR 1860 (F) 5 0-CCCAAGCTTGGCAGCGAGCATGGCTGG-30
(R) 50-ATAGGATCCCGCTCGCTCTGGTCAGC-30
MCAM-lD45 PCR 1806 (F) 5 0-CCCAAGCTTGGCAGCGAGCATGGCTGG-30
(R) 50-ATAGGATCCAAACCCTGCAGGAGCCCCGC-30
MCAM-lD41 PCR 1806 (F) 5 0-CCCAAGCTTGGCAGCGAGCATGGCTGG-30
(R) 50-ATAGGATCCAACCCCGCCTCTTCGGAAAG-30
MCAM-lD30 PCR 1773 (F) 5 0-CCCAAGCTTGGCAGCGAGCATGGCTGG-3 0
(R) 50-ATAGGATCCAATTCAACTACATTCTTGTC-30
MCAM-Dcyto PCR 1686 (F) 5 0-CCCAAGCTTGGCAGCGAGCATGGCTGG-30
(R) 50-CGGGATCCCGCAGGAAGTAAATGATGGAGCC-30
MCAM (LL/RM) PCR 1878 (F) 5 0-TCCGAAGAGGCGGGGCGAATGCAGGGTGCCAACGGC-30
(R) 50-GCCGTTGGCACCCTGCATTCGCCCCGCCTCTTCGGA-3 0
MCAM-lDext(12) PCR 1250 (F) 5 0-ATGTCTACGTGAACGTGAACGTCACTGTGTTC-30
(R) 50-ATTTAGGTGACACTATA-3 0
MCAM-lDext(345) 1080 (F) 5 0-CTAGCTAGCATCATCATCGTGGCCATCATC-30
(R) 50-ATTTAGGTGACACTATA-3 0
MCAM-lDext(12345) PCR 450 (F) 5 0-ATGTCTACCCATCGGAGAGCAAAGGC-30
(R) 50-ATGGATCCGAACACAGTGAC-3 0
MCAM-Dext(345)Dcyto PCR 820 (F) 5 0-CTAGCTAGCATCATCATCGTGGCCATCATC-30
(R) 50-CGGGATCCCGCAGGAAGTAAATGATGGAGCC-30
Primer design was based on previous studies [2,6]. Mutated nucleotides leading to LL mutation into RM are bold and underlined.
(F): forward, (R): reverse.
3650 B. Guezguez et al. / FEBS Letters 580 (2006) 3649–3656template were used in PCR under the following conditions: 18 cycles of
denaturation for 50 s at 95 C and primer annealing and extension at
68 C for 15 min. the primers used (mutated nucleotides are under-
lined) were shown in Table 1.
2.2. Cells, culture conditions and MDCK polarization
The mouse myogenic C2 cell line [20] and MDCK cells were grown
in Dulbecco’s modiﬁed Eagle medium (DMEM) plus Glutamax sup-
plemented with 10% heat-inactivated fetal calf serum and antibiotics
(Gibco Life Technologies Inc. UK). All cultures were performed in
5% CO2 humidiﬁed atmosphere at 37 C. Before culture, glass cover-
slips 22 · 22 mm (CML, France) were placed in 6-well plate (TPP,
Switzerland), sterilized by pure ethanol and air-dried at laminar ﬂow
of tissue culture cabinet for 2 h. For terminal polarization, MDCK
cells were seeded at conﬂuence in glass coverslips in culture medium
and cultured for 5–8 day. The cell polarization was controlled by
refringency of monolayer junctions with inverted phase-contrast
microscope.
2.3. Cell transfection and electroporation
Transfected L929 and MDCK cells expressing wild-type and mu-
tated MCAM-GFP were obtained after transfection of the relevant
expressions vectors using Lipofectamine 2000 reagent according to
the manufacturer’s recommendation (Invitrogen Inc.). Transfected
cells were maintained in culture medium supplemented with 1 mg/ml
neomycin (G418). Positive cells were detected and some of them were
conﬁrmed with sorted GFP populations using Phycoerythrine conju-
gated Anti-chicken MCAM (clone 264) by ﬂow cytometry (Coulter
Epics ﬂow cytometer; Beckman Coulter, Fullerton, CA, USA) and
by Western blotting of postnuclear lysates. Cells were then used either
for immunoﬂuorescence or confocal imaging.For transient expression, 5 · 106 C2 cells were electroporated (Easy-
ject Plus, Equibio, Ashford, UK) with 35 lg of MCAM-GFP or N-
Cad-GFP expression vectors under 260 V, 1500 lF in 400 lL DMEM
plus 15 mM HEPES, pH 7.2 (Invitrogen Inc.). The transfection eﬃ-
ciency was around 70% in all cases and the transfected cells were easily
identiﬁed by GFP expression with ﬂuorescence microscopy.
2.4. Antibodies and immunocytochemistry
Phycoerythrine conjugated monoclonal Anti-chicken MCAM (clone
264, [6]) was purchased from Southern Biotechnology and used for
ﬂow cytometry analyses.
For immunocytochemistry, MDCK transfected GFP cells were ﬁxed
with prewarmed 4% PBS-formaldehyde for 15 min. Thereafter, cells
were treated with 0.1% PBS-Triton for 10 min and soaked in blocking
solution (PBS containing 5% BSA) for 30 min. Coverslips were incu-
bated with monoclonal anti-E-cadherin (1/400 dilution, clone 36, BD
Biosciences) or monoclonal anti-ZO-1 (1/250 dilution, clone 1A12,
Zymed Laboratories) in 1% PBS-BSA for 1 h. Then, washed and incu-
bated with goat TRITC or Alexa Fluor 555-conjugated anti-mouse
antibodies (1/300 dilution, Molecular Probes).
C2 transfected GFP cells were incubated either with polyclonal anti-
b-catenin (1/500 dilution, Sigma) or polyclonal anti-phospho-FAK (1/
200, Santa Cruz Biotechnology) and then revealed with goat Alexa
Fluor 546-conjugated anti-polyclonal antibody (1/800 dilution,
Molecular Probes). For positive controls, the focal contacts were re-
vealed by anti-Rat b1 integrin (1/100, clone 9EG7, BD Pharmigen).
For cytoskeleton staining of L929 transfected GFP cells, TRITC-
conjugated phalloidin (1/1500 dilution, Sigma) were used to visualize
F-actin.
All procedures were performed at room temperature. Samples were
mounted in Immuno-mount (Thermo Shandon, Pittsburgh, USA)
and analysed with TCS-SP confocal microscope (Leica, Mannheim,
B. Guezguez et al. / FEBS Letters 580 (2006) 3649–3656 3651Germany) set on sequential mode. The images were treated with the
Metamorph software (Roper Scientiﬁc, Trenton, NJ) and Adobe
Photoshop software (Adobe Systems, USA).2.5. C2 cell adhesion assay
Glass coverslips were treated with 20% nitric acid, washed in meth-
anol–acetone and coated with organopolysiloxane (Sigmacote, Sigma,
Germany). Air-dried salinized coverslips were loaded with anti-mouse
Fcc fragment antibodies (Jackson ImmunoReasearch, West Grove,
PA, USA) at 1 lg/cm2 in 0.1 M borate buﬀer pH 8.0 for at least 5 h.
Coverslips were then incubated for 2 h with a concentration of 5–
10 lg/cm2 (as determined by dot blot analysis) of puriﬁed Ncad-Fc chi-
mera (extra-cellular domain of the chicken N-cadherin fused to the
mouse IgG2b Fcc fragment) [21]. Alternatively, coverslips were then
saturated with 1.5% puriﬁed BSA (Sigma, Germany) in borate buﬀer
for 5 min at room temperature. To preserve cell-surface cadherins,
C2 cells were mechanically dissociated in trypsin-free conditions withFig. 1. MCAM-l and MCAM-s are targeted to basolateral and apical memb
avian MCAM-l-GFP or MCAM-s-GFP prior to polarization. Double lab
detected by TRITC or Alexa Fluor555-conjugated secondary antibodies. Sca
membranes but the precision of these experiments did not allow to determine
MCAM-s are not components of tight junctions since no colocalization werPBS, 5 mM EDTA, 2% BSA on ice [21]. Cells were then plated on
the diﬀerent adhesion substrates in serum-free conditions and at very
low density (5 · 102–5 · 103 cells/cm2) for 2 h.3. Results
3.1. MCAM-l and MCAM-s are targeted to basolateral and
apical MDCK cell surfaces, respectively
GFP was inserted at the C-terminus of both avian MCAM
isoforms and transfected into epithelial MDCK II cells
(Fig. 1). These cells polarized spontaneously in vitro between
day 5 and day 8 of culture. Confocal microscopy revealed that
MCAM-l-GFP accumulated in basal and lateral membranes
where it colocalized with E-cadherin, a marker for the lateralranes of epithelial cells, respectively. MDCK cells were transfected by
eling was performed with anti-ZO-1 and anti-E-cadherin antibodies
le bar, 25 lm. (A) MCAM-l colocalized with E-cadherin on basolateral
if MCAM-l was targeted to adherens junctions. (B) MCAM-l as well as
e detected between MCAM isoforms and ZO-1.
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with ZO-1, a marker of tight junctions. In contrast, MCAM-
s-GFP accumulated at the apical membrane and did not colo-
calize either with ZO-1, the marker of tight junctions. ControlFig. 2. MCAM-l is not a component of adherens junctions and focal adhesion
MCAM-l-GFP transfected C2 cells were spread on Ncad-Fc for 2 h and immu
Catenin as well as N-cadherin staining presented a radial distribution in lamel
on the cell membrane. MCAM/b-catenin and N-cadherin co-localization was
cells. In contrast to N-cadherin and overlays revealed no colocalisation of M
obtained with untagged wild-type MCAM-l (not shown). Scale bar, 10 lm. (B
ﬁbronectin for 2 h and immunolabelled for b1-integrin (green) and for phosph
for phospho-FAK (red). The b1-integrin as well as phospho-FAK labeled foc
membrane. Scale bar, 10 lm. Inset: closer view of the focal contacts (arro
analysed on a 500 nm thin confocal section corresponding to the ventral side
focal adhesions. Similar results were obtained with untagged wild-type MCAexperiments were performed with wild-type MCAM-l and
MCAM-s isoforms, immunoﬂuorescence detection revealed
similar localization and established that GFP did not perturb
MCAM isoform targeting (not shown).s. (A) MCAM-l is not localized at adherens junctions. N-cad-GFP and
nolabelled for b-catenin (red) and analyzed by confocal microscopy. b-
lipodium (arrowheads) ; whereas MCAM-l was detected homogenously
analysed on a 500 nm thin confocal section taken at the ventral side of
CAM-l with the radial distribution of b-catenin. Similar results were
) MCAM-l is not localized at focal adhesions. C2 cells were spread on
o-FAK (red). MCAM-l-GFP transfected C2 cells were immunolabelled
al adhesions; whereas MCAM-l was detected homogenously on the cell
wheads). Scale bar: 5 lm. MCAM/phospho-FAK co-localization was
of cells. Overlays revealed no colocalisation of MCAM isoforms with
M-l (not shown).
B. Guezguez et al. / FEBS Letters 580 (2006) 3649–3656 36533.2. MCAM-l is not a component of adherens junctions and focal
adhesions
Since MCAM-l colocalized with E-cadherin on basal
membranes, MCAM-l could be a component of adherens
junctions such as the cadherins. To address this question,
we performed immmunolocalization analysis using a speciﬁc
assay in which cadherin-mediated contacts were increased
artiﬁcially by spreading cells directly onto a cadherin mim-
icking substrate as previously described [21]. MCAM-l-
GFP transfected myogenic C2 cells expressing endogenous
N-cadherin were allowed to attach at low density on an
immobilized Ncad-Fc. b-Catenin and N-cadherin were re-
cruited in radial structures linked to actin cytoskeleton and
mimicking adherens junctions, also named cadherin adhe-
sions. MCAM-l-GFP b-catenin double labeling revealed thatFig. 3. The dileucine motif 41-42 of the cytoplasmic domain targeted MCAM
and extracytoplasmic mutants of MCAM-l isoform. (B) MCAM-l mutant
MCAM-l-GFP constructs prior to polarization. Cells were ﬁxed with 4% p
MCAM-l and MCAM-lD45 were addressed to MDCK basolateral membrane
membranes. Extracellular domain mutants of MCAM-l (MCAM-lDext12345
Additional mutations of the cytoplasmic region including dileucine motif inc
bar, 25 lm.MCAM-l homogenously distributed on the lamellipodium
membrane was not further accumulated excluded in b-cate-
nin-positive radial structures (Fig. 2). This experiment
showed that MCAM-l is not recruited in actin/catenin-cad-
herin complexes.
In order to determine the possible involvement of MCAM-l
in focal adhesions, MCAM-l-GFP C2 transfected cells were
seeded on ﬁbronectin and focal adhesions revealed using an
anti-phospho-FAK antibody (Fig. 2). Double staining of
MCAM-l-GFP and phospho-FAK (or vinculin, not shown)
showed that MCAM-l was also excluded from focal adhesions.
C2 cell transfection of wild-type MCAM-l led to similar re-
sults, indicating that the GFP tag did not inﬂuence MCAM
localization with actin/catenin cadherin complex or with phos-
pho-FAK (not shown).-l to basolateral membranes of MDCK cells. (A) Panel of cytoplasmic
targeting in polarized MDCK cells. MDCK cells were transfected by
araformaldehyde. GFP detection with confocal microscope show that
s whereas MCAM-lD41 and MCAM-l (LL/RM) were targeted to apical
, and not shown) were targeted to basolateral and apical membranes.
reased apical targeting (MCAM-lDext345Dcyto and not shown). Scale
3654 B. Guezguez et al. / FEBS Letters 580 (2006) 3649–36563.3. The cytoplasmic dileucine motif 41-42 is required for
basolateral targeting of MCAM-l
In order to identify the motif in the cytoplasmic tail of
MCAM-l responsible for basolateral sorting, we created vari-
ous cytoplasmic MCAM-l mutants of MCAM-l-GFP (Fig. 3).
These mutants were checked in Western blot experiments using
an anti-GFP antibody and their expression on the cell surface
was established by ﬂow cytometry experiments using anti-
MCAM antibodies (not shown). Mutant lacking the last 22C-
terminal aminoacids (D59, D45) still localized to the basolateral
membrane (Fig. 3). However, when 24 ormore aminoacids were
deleted (D41, D30, D-cyto) MCAM-l-GFP was located on the
apical membrane, and showed no basolateral expression.More-
over the replacement of leucines 41-42 by arginine-methionine
led to apical location of the mutant MCAM-l-(LL/RM)-GFP
construct. The apical targeting of this MCAM-l-GFP chimeric
mutant protein thus shows that the dileucine motif at position
41-42 of the cytoplasmic tail of MCAM-l is critical for basolat-
eral sorting of MCAM-l. Transfection of MCAM-l-GFP mu-
tant deleted either for Ig domains 1 and 2, Ig domains 3,4, or
5, or the whole extracellular domain led to identical results.
TheseMCAM-l mutants were targeted to basolateral and apical
membranes. Thus,MCAM extracellular domain inﬂuences also
membrane targeting (Fig. 3 and not shown).4. Discussion
In this report we show that MCAM-s and MCAM-l were
addressed to apical membranes and basolateral surfaces of
polarized MDCK cells, respectively. Mutants of MCAM-l-Fig. 4. Functional motifs of MCAM-l and MCAM-s cytoplasmic domains.
chicken (cMCAM-s), murine (mMCAM-s), human (hMCAM-s), rat (rMCA
(blue triangle) and its C-terminus which might interact with a PDZ domain.
chicken (cMCAM-l), murine (mMCAM-l), human (hMCAM-l), rat (rMCAM
to the PKC site encountered in the MCAM-s cytoplasmic domain, MCAM-l
involved in MCAM-l induction of microvilli and of their extension in lympho
(orange) is required for basolateral targeting in MDCK cells. A putative end
tail. Note that these diﬀerent motifs are conserved in vertebrates.GFP chimeras allowed to establish that a single dileucine motif
(41-42) conserved during evolution controls MCAM-l basolat-
eral targeting (Fig. 4). The dileucine signal in MCAM-l is sim-
ilar to targeting motifs in other basolateral proteins including
numerous type I and type II cadherins [22,23], furin [24],
invariant chain [25], and LDL receptors [26]. In several cases,
such as furin, the dileucine motif has an acidic cluster on its
carboxy terminal side shown to be important for the function
of dileucine signal in basolateral targeting [22]. Such acidic
cluster is absent in MCAM-l as well as in the dileucine motif
of B-CAM, another V–V–C2–C2–C2 Ig molecule, which is
also targeted to basolateral membranes [27]. In contrast
MCAM-l dileucine motif (EExxLL) belongs to the family of
dileucine signals (D/ExxxLL) functioning in endocytosis or
endosomal–lysosomal targeting of transmembrane protein
[28]. The leucine residues of the EXXXLL motif found in
HIV Nef proteins were required for binding to adaptor protein
(AP-1 and AP-3) complexes of coated vesicles, inducing an
expansion of the endosomal compartment [29]. It is therefore
very likely that this MCAM-l motif will also function as an
endocytosis motif. In addition the YXXL (59–62) motif which
is not involved in MCAM-l basolateral sorting could also be
involved in the endocytosis process of this molecule [28].
Apical and basolateral targeting of MCAM-l-GFP con-
structs deleted for the whole extracellular domains shows that
the extracellular domain inﬂuence the basolateral targeting
similarly to other adhesion molecules of the Ig superfamily,
CEACAM-1 and PECAM-1 [30,31]. MCAM-l lateral localiza-
tion would be favored by homophilic or heterophilic binding
with molecules on the adjacent cells. In addition, MCAM ecto-
domain was found as soluble form in the culture media of hu-Alignment of aminoacid sequences of MCAM-s cytoplasmic region of
M-s) [2,6]. This sequence presents two conserved motifs, a PKC site
Alignment of aminoacid sequences of MCAM-l cytoplasmic region of
-l), zebraﬁsh (zMCAM-l) and bovine (bMCAM-l) [2,3,6]. In addition
exhibits a second PKC site (blue triangle). Serine 32 (red) of this site is
cytes and ﬁbroblasts (Guezguez et al., submitted). The dileucine motif
ocytosis motif YXXL is also encountered in the MCAM-l cytoplasmic
B. Guezguez et al. / FEBS Letters 580 (2006) 3649–3656 3655man endothelial cells [32,33]. Both MCAM isoforms might
exhibit diﬀerent susceptibility for proteolysis that could be
involved in the control of MCAM membrane distribution.
Our data suggest that MCAM-l did not localize at tight and
adherens junctions and conﬁrm a previous study showing that
in HUVECs MCAM did not colocalize with VE-cadherin or
PECAM-1 [15]. In addition to its expression at cell–cell junc-
tion, human MCAM was also detected on the apical side of
the HUVECs [15] in agreement with the expression of both
MCAM-l and MCAM-s isoforms in endothelial cell lines
and HUVECs [2], (Guezguez et al., submitted for publication).
In addition, our adhesion assay on ﬁbronectin suggests that
MCAM-l is located outside of focal adhesions but we cannot
exclude that MCAM-l is present in desmosomes as JAM-C
[34]. Whatever MCAM-l precise localization on basolateral
membranes, MCAM-l regulates cell–cell junctions since
MCAM-l overexpression in ﬁbroblasts decreased paracellular
permeability [15] and treatment of conﬂuent microvascular
endothelial cells with an anti-MCAM antibody increased per-
meability to albumin in vitro [17].
In mesenchymal cells, such as ﬁbroblasts, melanoma cells
and lymphocytes, MCAM-l induces microvilli formation and
extension and is expressed on these microvilli [35], (Guezguez
et al., submitted for publication). We recently established that
MCAM is involved in circulating cell homing. Lymphocyte
MCAM-l promotes tethering and rolling by microvilli induc-
tion and rolling receptor redistribution (Guezguez et al., sub-
mitted for publication). MCAM-l basolateral targeting in
epithelial cells and endothelium suggests that endothelial
MCAM-l plays a role in transendothelial migration, the last
step of leukocyte homing. Moreover, the diﬀerent localization
of MCAM-l in mesenchymal cells at top of microvilli promot-
ing migration and at cell–cell junctions in epithelial cells partic-
ipating to epithelium integrity may explain its dual roles in
tumor progression. Expression of MCAM-l in mesenchymal
cells such as melanoma or leukemia cells would favor invasion
and metastasis and promote tumor progression [1,36]. In con-
trast, MCAM-l involved very likely in cohesion of mammary
ductal and lobular epithelium, trophoblast and vascular endo-
thelium, acts as a tumor suppressor in breast carcinoma as well
as in infantile hemangioma [12,13,37].
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